EUROPEAN JOURNAL OF
PHARMACEUTICAL AND MEDICAL RESEARCH

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , 

 ISSN 2394-3211

Impact Factor: 6.222

 ICV - 79.57

Abstract

TUMOUR NECROSIS FACTOR ALPHA AND CANCER

Pragya Srivastava, Taniya* and Vaishali Bhagwani

ABSTRACT

Tumour necrosis factor-alpha (TNF-α, cachectin) is a member of the TNF superfamily. It was the first cytokine (cell signalling protein) to be evaluated for cancer biotherapy and its development. It is a multifunctional cytokine assuming a main job in apoptosis and cell survival just as in irritation and resistance. Still, the medical use of TNF-α is strictly limited by its noxiousness. Now, TNF-α is administered merely by locoregional drug delivery systems like isolated hepatic perfusion (IHP) and isolated limb perfusion (ILP). Meanwhile both of these processes are strictly challenging which require surgical procedure, they are chiefly used for the treatment of locally advanced sarcomas (solid tumours) like in-transit melanoma metastases, primary or metastatic unresectable liver carcinoma and limb- threatening soft tissue sarcomas. To decrease the toxicity in body of TNF-α, a number of schemes have been explored over the previous numerous decades. It has been exhibited in the detached appendage perfusion sitting that TNF-α acts synergistically with cytostatic drugs. The collaboration of TNF-α with TNF receptor 1 (TNFR-1) and TNF receptor 2 (TNFR-2) actuates a few flag transduction pathways, prompting the assorted elements of TNF-α. Tumour necrosis factor alpha produced mainly by activated macrophages, also it can be produced by many other cell types like mast cells (basophils), NK cells (natural killer cell), eosinophils (acidophils), CD4+ lymphocytes, neurons and neutrophils (polymorphs). It is involved in host defense and tissue homeostasis process. The biological effect of tumour necrosis factor alpha may ultimately beneficial or injurious to the host, depending on its period of tissue exposure, concentration and the existence of other mediators in the cellular environment. It shows antitumor activity and causes carcinoma, chronic inflammation, pulmonary, metabolic, cardiovascular, autoimmune and neurologic diseases.

Keywords: Interleukin, apoptosis, carcinoma, transferrin, tumour necrosis factor alpha.


[Full Text Article]

INDEXING

NEWS & UPDATION

  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 May 2020 Issue has been Published, Kindly check it on http://www.ejpmr.com/home/current_issues

  • EJPMR MAY ISSUE PUBLISHED

    MAY 2020 Issue has been successfully launched on 1 May 2020.

  • EJPMR New Impact Factor

    Its our Pleasure to Inform you that EJPMR Impact Factor has been increased from  5.804 to 6.222, due to high quality Publication at International Level

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 79.57, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process) IP Indexing (IP Value 2.40) Web of Science Group (Under Process) Directory of Research Journals Indexing